NCT06479356招募中2 期
An Open-Label, Single-Arm Study of Relma-cel, CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for Relapsed or Refractory (R/R) LBCL
Shanghai Ming Ju Biotechnology Co., Ltd.1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2024年8月15日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Objective response rate (ORR) in LBCL subjects
研究概览
简要总结
This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.
详细描述
This is an open-label, single-arm study conducted in adult subjects with R/R LBCL in China to evaluate efficacy，safety and pharmacokinetics(PK) of relma-cel.
Relma-cel was approved by the China National Medical Products Administration(NMPA)in September 2021(Acceptance No:CXSS2000036)for the treatment of adult patients with R/R LBCL after second-line or more systemic therapy.The recommended dose is 1×10^8 CAR+T cells.The indication for this application is R/R LBCL and the recommended dose is 1×10^8 CAR+T cells.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥18 years old;
- •Sign on the informed consent;
- •Subjects must have histologically confirmed Large B-cell Lymphoma;
- •Subjects had been treated with anthracyclines and rituximab(or other CD20-targeted antibodies) and had relapsed, failed to respond, or progressed after at least two lines of therapy including autologous hematopoietic stem cell transplantation(auto-HSCT);
- •Subjects have accessible PET-positive lesion and have measurable CT-positive lesion according to Lugano Classification;
- •Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1;
- •Adequate organ function;
- •Adequate vascular access for leukapheresis procedure;
- •Subjects who have previously received CD19 targeted therapy must confirm that lymphoma lesions still express CD19;
- •Women of childbearing potential must agree to use highly effective methods of contraception for 1 year after the last dose of Relma-cel;
- •Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method for 1 year after the last dose of Relma-cel.
排除标准
- •Primary CNS lymphoma;
- •History of another primary malignancy that has not been in remission for at least 2 years;
- •Subjects has HBV,HCV,HIV or syphilis infection at the time of screening;
- •Active deep venous thrombosis(DVT)/Pulmonary embolism(PE),or active DVT/PE requires anti-coagulation within 3 months prior to signing the ICF;
- •Subjects with uncontrolled systemic fungal,bacterial,viral or other infection;
- •Presence of acute or chronic graft-versus-host disease(GVHD);
- •History of any serious cardiovascular disease or presence of clinically relevant CNS pathology;
- •Pregnant or nursing woman;
- •Subjects using of any chemotherapy,corticosteroid,experiment agents,GVHD therapies,radiation,allo-HSCT or any other therapies for lymphoma must go through a specific wash-out period before leukapheresis;
- •Uncontrolled conditions or unwillingness or inability to follow the procedures required in the protocol;
- •Received CAR T-cell or other genetically-modified T-cell therapy previously.
研究组 & 干预措施
Relma-cel
Experimental
Efficacy, safety and PK of Relma-cel will be evaluated in 1 x 10^8 CAR+T cells dose level
干预措施: Relma-cel (Biological)
结局指标
主要结局
Objective response rate (ORR) in LBCL subjects
时间窗: 3 months
Objective response rate (ORR) in 3 month evaluated by investigator of LBCL subjects
次要结局
- Complete response rate (CRR) in LBCL subjects(up to 1 year after Relma-cel infusion)
- Progression-free survival (PFS)(up to 1 year after Relma-cel infusion)
- Objective response rate (ORR)(3 months)
- Duration of response (DOR)(up to 1 year after Relma-cel infusion)
- Pharmacokinetic(PK)-Tmax of Relma-cel(up to 1 year after Relma-cel infusion)
- Pharmacokinetic(PK)-AUC of Relma-cel(up to 1 year after Relma-cel infusion)
- Best objective response rate ( Best ORR) in LBCL subjects(up to 1 year after Relma-cel infusion)
- Overall survival (OS)(up to 1 year after Relma-cel infusion)
- Pharmacokinetic(PK)-Cmax of Relma-cel(up to 1 year after Relma-cel infusion)
- Adverse events (AEs)(up to 1 year after Relma-cel infusion)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell LymphomaDiffuse Large B Cell LymphomaLymphoma, Non-HodgkinNCT06149169Shanghai Ming Ju Biotechnology Co., Ltd.10
Unknown
1 期
Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell MalignanciesB Cell LymphomaAcute Lymphoblastic LeukemiaNCT04008251Wuhan Sian Medical Technology Co., Ltd10
招募中
早期 1 期
CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell MalignanciesRelapsed or Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B-cell Non-hodgkin LymphomaNCT05105867920th Hospital of Joint Logistics Support Force of People's Liberation Army of China15
Unknown
1 期
CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell MalignanciesB Cell LymphomaAcute Lymphoblastic LeukemiaNCT02965092Wuhan Sian Medical Technology Co., Ltd80
已完成
1 期
CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies PatientsB Cell MalignancyNCT03953599Hebei Yanda Ludaopei Hospital18